SINGAPORE, April 16, 2026 /PRNewswire/ — Digital travel platform Agoda has revealed that Chiang Mai has emerged as the top destination in Asia for culinary activities, based on activities booked on Agoda from January to March this year. For travelers eager to explore cooking classes, Bangkok, Hoi An, Ho Chi Minh City, and Hanoi round out the top five, underscoring the appeal of Thailand and Vietnam as culinary hubs in Asia.

It’s clear that food-forward activities are increasingly driving travel decisions. Agoda’s 2026 Travel Outlook Report highlights that culinary experiences have climbed into the top three motivators for Asian travelers, jumping from sixth place last year. Cooking classes, in particular, offer a unique way to immerse oneself in a destination’s culture, providing hands-on experiences that bring local traditions and flavors to life.

Here are the top five destinations for culinary enthusiasts, as identified by Agoda:

1. Chiang Mai, Thailand

Travelerscan engage in a hands-on culinary course in a local home and learn about traditional Thai ingredients through a guided tour of an organic farm. Before cooking, select fresh eggs or learn a unique coconut scraping technique. Travelers can discover authentic northern Thai specialties such as Khao Soi (coconut curry noodles) and Kaeng Hang Lei (ginger-tamarind pork curry).

2. Bangkok, Thailand

In the bustling district of Silom, travelers can participate in cooking classes led by expert instructors. These sessions include market visits to select fresh ingredients and lessons on preparing iconic dishes such as Tom Yum, Pad Thai, and various curries. Each day of the week features a different set menu, allowing participants to explore a wide range of Thai flavors and take-home recipes to recreate their favorite dishes.

3. Hoi An, Vietnam

Hoi An offers an exciting blend of cultural and culinary experiences for the food-lover and adventurer alike. At Cam Thanh coconut water village, travelers can enjoy a basket boat ride through the Bay Mau Nipa forest and discover traditional crab fishing methods. The experience provides a unique glimpse into the countryside and daily life of central Vietnam, with opportunities to master Vietnamese cuisine under the guidance of skilled local chefs.

4. Ho Chi Minh City, Vietnam

In the heart of the city, travelers can partake in a 3-course cooking class to prepare classic Vietnamese dishes, each menu carefully curated to highlight the unique flavors and cultural heritage of Vietnam. Those that prefer a specialty drink can opt for the egg coffee class, celebrating Vietnam’s renowned coffee culture. Travelers can also take a day trip to the Mekong Delta to explore local villages and sample regional specialties, including a workshop to learn how to make coconut candies.

5. Hanoi, Vietnam

Participants will prepare dishes like Pho bo (beef noodle soup), Bun cha (grilled pork with vermicelli), and Nem ran (fried spring rolls), enjoying their creations alongside classmates and sampling local rice wine. The experience includes a cookbook and certificate, allowing travelers to take home a piece of Hanoi’s culinary heritage.

Krishna Rathi, Associate Vice President at Agoda, shared, “Culinary experiences are a gateway to understanding a culture, and at Agoda, we are thrilled to connect travelers with these enriching opportunities. In Asia, Thailand and Vietnam stand out as culinary hubs, with rich flavors and an exciting selection of immersive experiences to choose from. Agoda makes it easy to book a wide range of activities alongside flights and accommodations for a seamless connected trip.” 

Travelers seeking unique experiences can browse over 300,000 activities, along with more than 6 million holiday properties and over 130,000 flight routes, all of which can be combined in the same booking. Discover the best deals on Agoda’s mobile app or visit Agoda.com for more.

Source

SHANGHAI, April 16, 2026 /PRNewswire/ — INS Land, a multi-story nightlife and entertainment complex in the heart of Shanghai, ranks No.12 in the 2026 Top 100 Clubs poll by DJ Mag. The achievement marks the highest ranking by a Chinese club and positions INS Land as the third highest-ranked venue in Asia in 2026.

In its debut year on the list, INS Land is Asia’s highest new entrant—a sign of its rapid global rise and second worldwide. The annual ranking, publicly voted by electronic music fans worldwide, is widely regarded as a key benchmark in global nightlife culture.

“This is an incredible achievement for our venue for China’s entertainment industry,” said Leo Liu, the Partner and Head of Global Business at INS Land.

 “As our first year participating, we are proud to stand alongside some of the world’s most established clubs. INS Land is more than a party destination—it has become a cultural landmark in Shanghai. We continuously reinvent the space with new concepts, and last November, it was the afterparty for Tomorrowland’s first China show.”

“As we celebrate our third year, we look ahead to updating the space with new concepts and expanding across Asia. Together with our partner Hero Esports, we aim to bring innovative and immersive experiences to audiences in China and beyond,” said Leo Liu.

Approaching its third anniversary on June 16, INS Land has redefined nightlife with its ‘club cluster’ concept. The venue brings together nine distinct clubs within a single building, each dedicated to different music genres and immersive environments. From electronic and hip-hop to live performances, the space offers a dynamic experience under one roof.

Beyond nightlife, INS Land has become a cultural landmark, integrating music, design, dining, and social experiences. The venue also played a destination for major esports launch events like the Hero Esports’ Asian Champions League and the official afterparty destination for Tomorrowland’s first edition in China. These partnerships further highlight INS Land’s global cultural connections and dedication to bringing exciting global concepts to China.

INS Land, together with its partners at Hero Esports—Asia’s largest esports organization—continues to expand  entertainment and youth culture.

Looking forward, INS Land plans to accelerate its expansion, launching sister venues in major Asian cities while continuing to push the boundaries of next-generation entertainment experiences.

Source

Based on preliminary internal assessments, these initiatives may contribute approximately $10 million in incremental revenue in the next fiscal year, subject to execution and market conditions

BEIJING, April 15, 2026 /PRNewswire/ — Datasea Inc. (NASDAQ: DTSS) (“Datasea” or the “Company”), a technology company specializing in acoustic high-tech innovation and AI-driven multimodal digitalization, today announced continued progress in the international commercialization of its acoustic technology-enabled head-focused health and wellness care robot business, alongside preparations for the U.S. market launch of its acoustic disinfection product line.

Building on previously disclosed developments, Datasea is advancing the commercialization of its wellness care robot solutions across China, broader international markets, and the United States through collaboration with strategic partners. In China, related products and services have been deployed in more than 50 cities across approximately 300 service locations. Internationally, the Company has established market cooperation in multiple Asian markets, including South Korea, Hong Kong SAR, Taiwan region, Singapore, Indonesia, and Malaysia. In the United States, Datasea has initiated early-stage commercial rollout activities, including pilot deployments and customer engagements in Boston, New Jersey, Los Angeles, and Phoenix. These developments reflect the Company’s efforts to establish a scalable commercialization pathway for its acoustic technology-enabled wellness solutions across multiple geographic markets.

In parallel, Datasea announced that its acoustic disinfection products, including its Smart Air Sterilizer, have completed overseas testing and certification procedures and are now preparing for commercial launch in the United States. As disclosed in the Company’s Annual Report on Form 10-K for the fiscal year ended June 30, 2025, the Company plans to advance U.S. market sales of these products through Datasea Acoustics LLC, its wholly owned Delaware subsidiary.

The Smart Air Sterilizer is designed for air disinfection and environmental hygiene applications, supporting pathogen reduction and improved air quality in both household and commercial settings. The product is intended for use across a range of environments, including homes, healthcare-related settings, hotels, airports, schools, and other public spaces. The Company believes that the combination of its acoustic technology capabilities, smart-environment application potential, and adaptability across multiple usage scenarios may provide a differentiated value proposition as it prepares for U.S. market entry.

The Company’s commercialization approach is centered on proprietary products and intellectual property, acoustic technology-enabled solutions, and scalable deployment across healthcare, wellness, beauty service, and consumer care environments. Datasea believes that, as market access and customer adoption continue to expand, this model may support multiple revenue streams, including hardware product sales, technical service fees, solution integration revenues, and recurring service-based revenues associated with deployed terminals and operating scenarios. The Company believes that the parallel advancement of its wellness care robot business and acoustic disinfection product line further demonstrates the expanding commercial applicability of its acoustic technology platform, and that these two product and solution lines may serve as complementary components of its broader acoustic high-tech commercialization strategy across the United States and international markets.

Based on preliminary internal assessments, the Company believes that, if current commercialization initiatives progress as expected, these businesses may have the potential to contribute up to approximately $10 million in incremental revenue in the next fiscal year. Such estimates are based on current internal expectations and are subject to significant uncertainties, including the pace of market adoption, execution progress, customer demand, channel performance, regulatory considerations, and other factors. There can be no assurance that such results will be achieved.

Ms. Zhixin Liu, Chief Executive Officer of Datasea Inc., commented:

“We believe the continued expansion of our acoustic technology-enabled wellness care robot business across China, international markets, and the United States, together with the planned U.S. launch of our acoustic disinfection products following overseas testing and certification, represents meaningful progress in the commercialization of our acoustic technology platform.

By advancing multiple product and solution lines in parallel, we are establishing a broader commercial foundation for our acoustic high-tech business across healthcare, wellness management, intelligent service, and environmental hygiene applications. We remain focused on disciplined execution and market rollout as we continue to expand our presence across domestic and international markets.

Based on our preliminary internal assessments, we believe these initiatives may create an incremental revenue opportunity of approximately $10 million in the next fiscal year, although actual results will depend on market adoption, execution progress, and overall operating conditions.”

The Company notes that both the expansion of its wellness care robot business and the U.S. commercialization of its acoustic disinfection products remain subject to execution progress, market conditions, and other uncertainties, and there can be no assurance regarding the timing, scale, or financial impact of these initiatives.

For additional information regarding the Company’s financial results and operations, please refer to the Company’s filings with the U.S. Securities and Exchange Commission.

About Datasea Inc.

Datasea Inc. (“Datasea”) is a leading provider of products, services, and solutions for enterprise and retail customers in two innovative industries, acoustic high tech and 5G-AI multimodal digitalization. The Company’s advanced R&D technology serves as the core infrastructure and backbone for its products. Its 5G multimodal digital segment operates on a cloud platform based on AI. Datasea leverages cutting-edge technologies, precision manufacturing, and ultrasonic, infrasound and directional sound technology in its acoustics business to combat viruses and prevent human infections, and it is also developing applications in medical ultrasonic cosmetology. In July 2023, Datasea established a wholly-owned subsidiary, Datasea Acoustics LLC, in Delaware, in a strategic move to enter the U.S. markets and to mark its global expansion plan. For additional information, please visit www.dataseainc.com.

Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934 and as defined in the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as “will”, “expects”, “anticipates”, “future”, “intends”, “plans”, “believes”, “estimates”, “target”, “going forward”, “outlook,” “objective” and similar terms. Such statements are based upon management’s current expectations and current market and operating conditions, and relate to events that involve known or unknown risks, uncertainties and other factors, all of which are difficult to predict and which are beyond Datasea’s control, which may cause Datasea’s actual results, performance or achievements (including the RMB/USD value of its anticipated benefit to Datasea as described herein) to differ materially and in an adverse manner from anticipated results contained or implied in the forward-looking statements. Further information regarding these and other risks, uncertainties or factors is included in Datasea’s filings with the SEC, which are available at www.sec.gov. Datasea does not undertake any obligation to update any forward-looking statement as a result of new information, future events or otherwise, except as required under law.

Investor and Media Contact: 

Datasea Investor Relations
Email: investorrelations@shuhaixinxi.com 
sunhezhi@shuhaixinxi.com 

Precept Investor Relations LLC

David Rudnick
+1 646-694-8538
david.rudnick@preceptir.com

Source: Datasea Inc.

Source

One of the world’s most extraordinary artistic achievements is set to be experienced in a completely new way, as Sistine Chapel: Revelations – An Immersive Exhibition prepares to open in Sydney.

SYDNEY, AUSTRALIA – 16th May – 19th July

SYDNEY, April 15, 2026 /PRNewswire/ — Developed by the Catholic Archdiocese of Sydney with the express permission and support of the Vatican, the exhibition brings together immersive technology, large-scale projection, and spatial storytelling, enabling audiences to experience the beauty of the Sistine Chapel like never before.

Sistine Chapel Revelations

Created for a broad audience—including art and culture lovers, families, students, tourists, and the spiritually curious—it seeks to bring to life the iconic works of Michelangelo and other Renaissance masters through a guided encounter with the story and symbolism behind the art.

This exhibition offers a rare opportunity to encounter one of the greatest treasures of Western civilisation in a new way. “This is about giving people the chance to experience one of the great works of human genius in a way that feels intimate and alive,” said Juliette Khoury, Archdiocesan Project Lead. “The Sistine Chapel is more than a masterpiece; it is a place where art, story, and the sacred meet. This exhibition invites people to step into that encounter.”

The Sydney opening marks the beginning of a global journey for the exhibition, with the potential to reach international audiences in the years ahead.

Visitors will be guided through the narrative that adorns the ceiling and walls, from Creation to the Fall, from Redemption to Judgement, illuminating the meaning behind the imagery and its enduring relevance today.

Sistine Chapel: Revelations is expected to be one of Sydney’s most significant cultural events in recent years, offering an experience that bridges art, faith, technology, and history in a way rarely seen at this scale. It will stand alongside leading immersive experiences worldwide, the likes of the recent Van Gogh exhibitions, Japan’s teamLab, and the United States’ Meow Wolf.

The exhibition runs from 16 May to 19 July at the forecourt of St Mary’s Cathedral, Sydney, housed in a custom-built truss structure that captures the breathtaking proportions of the Sistine Chapel.

For more information, please visit https://sistinechapelsydney.com.au/?utm_source=Pi&utm_medium=Newswire&utm_campaign=awareness&utm_id=Sistenechapelsydney&utm_term=masterpieces&utm_content=prarticle

Source

MELBOURNE, Australia and INDIANAPOLIS, April 15, 2026 /PRNewswire/ — Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today announces that the first patient has been dosed with TLX101-Tx (¹³¹I-iodofalan) in Telix’s pivotal IPAX BrIGHT trial^[1], marking the first radiopharmaceutical therapy to enter Phase 3 development for glioblastoma, an aggressive form of brain cancer.

The patient was dosed at Austin Health in Melbourne, Australia, under the supervision of Professor Hui Gan. IPAX BrIGHT is assessing the safety and efficacy of TLX101-Tx in combination with chemotherapy (lomustine), compared to chemotherapy alone. The global, multicenter, open-label study will enroll patients with radiographically confirmed recurrent glioblastoma at first recurrence.

Telix’s commitment to advancing care for patients with glioblastoma is driven by the significant unmet need in this space. In the past 25 years, only two drugs have been approved by the United States Food and Drug Administration (FDA) for glioblastoma^[2], and no standard treatment currently exists for recurrent disease. Patients therefore face limited treatment options after initial therapy. TLX101-Tx offers a novel approach by targeting the L-type amino acid transporter 1 (LAT1), a transporter that enables the radiopharmaceutical to cross the blood-brain barrier and delivers therapy directly to the tumor.

IPAX BrIGHT expands upon promising data from earlier trials in the recurrent glioblastoma setting, including IPAX-1^[3], which reported a median overall survival (OS) of 13 months from the initiation of treatment with TLX101-Tx, or 23 months from initial diagnosis^[4]. Preliminary results from the IPAX-Linz investigator-initiated trial of TLX101-Tx were consistent and confirmatory to IPAX-1, with a median OS of 12.4 months from initiation of treatment and 32.2 months from initial diagnosis^[5]. Beyond the clinical trial setting, an early access program for TLX101-Tx in Europe has dosed 18 patients at first recurrence or later, further establishing the clinical utility of TLX101-Tx.

Professor Gan, Director of Cancer Clinical Trials at Austin Health, said, “Based on the prior safety profile and early efficacy data for TLX101-Tx in the IPAX-1 and IPAX-Linz studies, I am pleased to continue to explore this therapeutic modality in the first radiopharmaceutical pivotal trial in recurrent glioblastoma, where there are currently few effective treatment options.”

Dr. David N. Cade, Group Chief Medical Officer, Telix, added, “Through the IPAX BrIGHT trial, we aim to offer a new option for patients affected by glioblastoma. This registration-enabling study represents a major step forward in our mission to improve therapeutic options in neuro-oncology. With very limited innovation in treatment in recent decades, TLX101-Tx has the potential to become a first-in-class therapy that meaningfully improves patient outcomes.”

The IPAX BrIGHT study has received regulatory approval in Australia, Austria, Belgium and the Netherlands with approval being sought in additional jurisdictions. Telix’s investigational PET^[6] imaging agent for glioma, TLX101-Px (floretyrosine F 18) will be used for patient selection in IPAX BrIGHT, as well as assessing metabolic tumor response according to PET RANO 1.0^[7].

About TLX101-Tx

TLX101-Tx (¹³¹I-iodofalan) is a systemically administered radiopharmaceutical therapy that targets L-type amino acid transporter 1 (LAT1), which is typically over-expressed in glioblastoma. TLX101-Tx utilizes a small molecule approach due to the need to cross the blood brain barrier, the normal protective barrier that prevents many potential drug candidates entering the brain. In addition to the IPAX-1 and IPAX-Linz studies, TLX101-Tx is also under investigation in the IPAX-2 Phase 1 study in combination with post-surgical standard of care treatment in patients with newly diagnosed glioblastoma^[8]. TLX101-Tx has received orphan drug designation in the U.S. and Europe for the treatment of glioma. TLX101-Tx and TLX101-Px have not received a marketing authorization in any jurisdiction.

About glioblastoma  

Glioblastoma (GBM), is a high-grade glioma and the most common and aggressive form of primary brain cancer, with approximately 22,000 new cases diagnosed annually in the U.S.^[9]. The mainstay of treatment for GBM comprises surgical resection, followed by combined radiotherapy and chemotherapy. Despite such treatment, recurrence occurs in almost all patients^[10], with an expected survival duration of 12-15 months from diagnosis^[11].

About Telix Pharmaceuticals Limited

Telix is a global biopharmaceutical company focused on the development and commercialization of radiopharmaceuticals with the goal of addressing significant unmet medical need in oncology and rare diseases. Telix is headquartered in Melbourne (Australia) with international operations in the United States, United Kingdom, Brazil, Canada, Europe (Belgium and Switzerland) and Japan. Telix is listed on the Australian Securities Exchange (ASX: TLX) and the Nasdaq Global Select Market (NASDAQ: TLX).

Visit www.telixpharma.com for further information about Telix, including details of the latest share price, ASX and U.S. Securities and Exchange Commission (SEC) filings, investor and analyst presentations, news releases, event details and other publications that may be of interest. You can also follow Telix on LinkedIn, X and Facebook.

Media Contact

Eliza Schleifstein
917.763.8106 (Mobile)
Eliza@schleifsteinpr.com

Legal Notices

Cautionary Statement Regarding Forward-Looking Statements. 

You should read this announcement together with our risk factors, as disclosed in our most recently filed reports with the Australian Securities Exchange (ASX), U.S. Securities and Exchange Commission (SEC), including our Annual Report on Form 20-F filed with the SEC, or on our website.

The information contained in this announcement is not intended to be an offer for subscription, invitation or recommendation with respect to securities of Telix Pharmaceuticals Limited (Telix) in any jurisdiction, including the United States. The information and opinions contained in this announcement are subject to change without notification. To the maximum extent permitted by law, Telix disclaims any obligation or undertaking to update or revise any information or opinions contained in this announcement, including any forward-looking statements (as referred to below), whether as a result of new information, future developments, a change in expectations or assumptions, or otherwise. No representation or warranty, express or implied, is made in relation to the accuracy or completeness of the information contained or opinions expressed in the course of this announcement.

This announcement may contain forward-looking statements, including within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, that relate to anticipated future events, financial performance, plans, strategies or business developments. Forward-looking statements can generally be identified by the use of words such as “may”, “expect”, “intend”, “plan”, “estimate”, “anticipate”, “believe”, “outlook”, “forecast” and “guidance”, or the negative of these words or other similar terms or expressions. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to differ materially from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. Forward-looking statements are based on Telix’s good-faith assumptions as to the financial, market, regulatory and other risks and considerations that exist and affect Telix’s business and operations in the future and there can be no assurance that any of the assumptions will prove to be correct. In the context of Telix’s business, forward-looking statements may include, but are not limited to, statements about: the initiation, timing, progress, completion and results of Telix’s preclinical and clinical trials, and Telix’s research and development programs; Telix’s ability to advance product candidates into, enroll and successfully complete, clinical studies, including multi-national clinical trials; the timing or likelihood of regulatory filings and approvals for Telix’s product candidates, including TLX101-Px and TLX250-Px, manufacturing activities and product marketing activities; Telix’s sales, marketing and distribution and manufacturing capabilities and strategies; the commercialization of Telix’s product candidates, if or when they have been approved; Telix’s ability to obtain an adequate supply of raw materials at reasonable costs for its products and product candidates; estimates of Telix’s expenses, future revenues and capital requirements; Telix’s financial performance; developments relating to Telix’s competitors and industry; the anticipated impact of U.S. and foreign tariffs and other macroeconomic conditions on Telix’s business, including as a result of war or other geopolitical conflicts; and the pricing and reimbursement of Telix’s product candidates, if and after they have been approved. Telix’s actual results, performance or achievements may be materially different from those which may be expressed or implied by such statements, and the differences may be adverse. Accordingly, you should not place undue reliance on these forward-looking statements.

Trademarks and Trade Names. All trademarks and trade names referenced in this press release are the property of Telix Pharmaceuticals Limited (Telix) or, where applicable, the property of their respective owners. For convenience, trademarks and trade names may appear without the ® or ™ symbols. Such omissions are not intended to indicate any waiver of rights by Telix or the respective owners. Trademark registration status may vary from country to country. Telix does not intend the use or display of any third-party trademarks or trade names to imply any affiliation with, endorsement by, or sponsorship from those third parties.

©2026 Telix Pharmaceuticals Limited. All rights reserved.

Source

CONNECTING EXPERIENCES – PROMOTING CUISINE – ADVANCING DIGITAL TOURISM

HO CHI MINH CITY, Vietnam, April 14, 2026 /PRNewswire/ — Following the successful conclusion of the Ho Chi Minh City Tourism Festival 2026 on April 5, Grab Vietnam’s participation stood out by enhancing visitor experiences and heavily promoting the City’s image across digital platforms to the summer tourism market.

A key highlight was the “Ho Chi Minh City Iconic Eateries” Awards 2026, honoring 60 outstanding restaurants and eateries — well-loved destinations that represent the rich culinary identity of the City. The program was developed based on data from the GrabFood platform combined with on-ground evaluations, following rigorous criteria.

The awarded establishments were categorized into three groups:

• Local Flavor Legends (40 establishments): representing local culinary identity;
• Customer Choice: Best Experience (10 establishments): recognized for outstanding service quality;
• Rising Stars (10 establishments): acknowledging impressive growth and strong adaptability on digital platforms.

In addition, Grab introduced various solutions to support visitors, notably the Travel Pass package designed for international travelers. Integrated within the Grab app, it offers bundled services including transportation, dining, and shopping at optimized costs, with total benefits of up to nearly VND 2.5 million per package.

At the same time, dedicated ride-hailing support zones, interactive experience areas, and on-site promotional offers at the event enabled visitors to easily access services and discover the “Iconic” eateries.

Mrs. Nguyen Thanh Anh, Director of Marketing and Commercial Operations at Grab Vietnam, stated that the initiative aims to honor local culinary values while bringing these experiences closer to residents and tourists through technology platforms.

The collaboration between the Ho Chi Minh City Department of Tourism and Grab Vietnam demonstrates the effectiveness of partnership models in developing tourism integrated with technology. This marks an important step toward enhancing visitor experiences, accelerating digital transformation, and positioning Ho Chi Minh City as a modern, friendly, and culturally rich destination.

Source